Last year, Spanish dermatology firm Almirall entered a license and commercialization agreement with Danish MC2 Therapeutics, gaining the European rights for the latter company’s plaque psoriasis cream, Wynzora.
Almirall has now initiated the launch of the cream in Europe, the company announces in a press release.
The rollout will begin on the Spanish, German and UK markets, with more European markets expected to follow in coming months.
”The launch of Wynzora cream in Europe represents a step forward in our commitment to offering innovative therapies that improve the quality of life of patients with psoriasis,” says CEO at Almirall Gianfranco Nazzi in the statement, adding:
”Currently, 73 percent of patients are not adhering to topical treatments. In view of this worrying lack of adherence to such treatments, Almirall is convinced that this new product, with proven efficacy and a patient-friendly formulation, will mark a turning point by improving psoriasis patients’ satisfaction thanks to its less greasy formulation.”
MC2 Therapeutics launched Wynzora on the US market last year, in a collaboration with Epi Health.
Express Scripts to cover psoriasis cream from MC2 Therapeutics
MC2 Therapeutics launches psoriasis cream in US
Almirall partner MC2 on the verge of EU victory after ten years of hard work
More from MedWatch
WS Audiology brings in head of EMEA region from Coloplast
The hearing aid manufacturer has appointed Coloplast’s now outgoing president for emerging markets as president for the EMEA region.
Dupixent could dominate pediatric eczema market for up to a decade, analysis finds
Sanofi and Regeneron will be able to call themselves market leaders within atopic eczema treatment for children aged 6 months to 5 for years to come, according to Globaldata.
FDA advisors support approval for Ferring's intestinal infection medicine
All signs indicate that Ferring Pharmaceuticals is on the cusp of being market authorized for its biologic candidate against C. difficile infection.
Pharmacosmos expects massive growth in four years
The company’s new chief executive has ambitions of reaching a DKK 2.5bn (USD 325m) revenue within the time frame.
The Lundbeck Foundation, ATP, LEGO asset manager join forces on secretive project
Three of Denmark’s biggest funds have come together for a yet unknown project, which includes the establishment of three new firms.
eTMF Manager 
Ambitious Business Relationship Manager for the Danish Medicines Agency 
Drug Safety Associate 
Chief Business Officer 
Pharmacovigilance & Regulatory Officer 
Senior Manager, System Change & Release Management 
Nordic Key Account Manager, Hollister & Dansac 
Regulatory Project Manager 
KLIFO is looking for a Compliance Coordinator for our Glostrup office 
Scientist Radiochemistry 
Senior/lead consultant at Emendo Engineering 
Clinical Project Lead 
Manager of QA, BHS Logistics 
Product specialist 
Senior CMC Regulatory Manager